MNKD Share Price Performance
US$3.28
-1.85 (-36.06%)
65.9% undervalued intrinsic discount
US$9.61
Fair Value
Price US$3.28
AnalystConsensusTarget US$9.61
AnalystLowTarget US$7.50
AnalystHighTarget US$12.00
Fair ValueUS$9.61
Share Pricen/a
MannKind Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
MNKD Community Narratives
AN
Fair Value US$9.61 65.9% undervalued intrinsic discount
Pipeline Advancements And International Expansion Will Shape Future Markets
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$7.5 56.3% undervalued intrinsic discount
Slow Formulary Coverage Will Hamper Diabetes Reach Yet Enable Rebound
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$14.69 77.7% undervalued intrinsic discount
Inhaled Therapies Will Expand Global Diabetes And Pulmonary Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Slow Formulary Coverage Will Hamper Diabetes Reach Yet Enable Rebound
Key Takeaways Limited awareness, slow market penetration, and rising competition from large pharma constrain growth and earnings potential, despite strong trends favoring MannKind's inhaled therapies. Heavy dependence on a narrow pipeline, escalating expenses, and external pricing pressures threaten financial stability and delay meaningful profitability improvements.Read more
34
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$7.5
56.3% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
12.36% p.a.
Profit Margin
9.64%
Future PE
68.22x
Price in 2029
US$9.24
Pipeline Advancements And International Expansion Will Shape Future Markets
Key Takeaways Afrezza's growth, new indications, and expanded global reach support higher revenue, with inhaled pipeline progress promising significant future diversification. Strategic financing, high-margin royalties, and broader marketing efforts strengthen cash flow, margins, and reduce reliance on equity funding.Read more
466
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$9.61
65.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
21.58% p.a.
Profit Margin
20.25%
Future PE
32.95x
Price in 2029
US$11.88
Inhaled Therapies Will Expand Global Diabetes And Pulmonary Markets
Key Takeaways MannKind is poised for significant revenue and margin growth driven by strong product portfolio momentum, aggressive commercialization, and favorable market trends in inhaled therapeutics. The company's cash position and unique platform enable rapid expansion, portfolio evolution, and potential transformative partnerships, with consensus underestimating its long-term profitability.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$14.69
77.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
15.89% p.a.
Profit Margin
21.57%
Future PE
66.28x
Price in 2028
US$17.87
Trending Discussion
Recently Updated Narratives
AN
MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case
Fair Value: US$7.5 56.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside Potential
Fair Value: US$9.61 65.9% undervalued intrinsic discount
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Inhaled Therapies Will Expand Global Diabetes And Pulmonary Markets
Fair Value: US$14.69 77.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MannKind Corporation Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 0.019
- 74.79%
- 1.68%
- -695.1%
About MNKD
- Founded
- 1991
- Employees
- 405
- CEO
- WebsiteView website
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, an furosemide injection for the treatment of edema in pediatric patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. The company was incorporated in 1991 and is headquartered in Danbury, Connecticut.
